Status:
UNKNOWN
The Whole-course Management of Pegaspargase in ENKTL
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University
Conditions:
Extranodal NK/T Cell Lymphoma
Eligibility:
All Genders
Phase:
NA
Brief Summary
This is a prospective, multi-center study of the whole-course management of pegaspargase in Extranodal NK/T cell lymphoma (ENKTL). Based on a complete population pharmacokinetic model of pegaspargase ...
Eligibility Criteria
Inclusion
- Pathologically confirmed first-line ENKTL patients according to WHO 2016
- Willingness to provide written informed consent.
Exclusion
- Patients are unsuitable for the enrollment according to investigator's judgement.
Key Trial Info
Start Date :
July 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 15 2025
Estimated Enrollment :
72 Patients enrolled
Trial Details
Trial ID
NCT05426824
Start Date
July 1 2022
End Date
July 15 2025
Last Update
June 22 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hematological Department, People's Hospital of Jiangsu Province
Nanjing, Jiangsu, China, 210029